Press Releases
Page 1 of 25
Summary of Onxeo’s Liquidity Contract with Kepler Cheuvreux
July 3, 2020 – 6:00 pm CEST Pursuant to the liquidity contract granted to Kepler Cheuvreux regarding Onxeo shares, […]
Tags: Financials & Corporate
07/03/2020
Onxeo Confirms in Preclinical Studies the Profile of OX401, a Potent PARP Agonist with Strong Anti-Tumor Activity and Immunological Properties
Paris (France), June 25, 2020 – 7.00 am CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]
Tags: OX401
06/25/2020
New AsiDNA™ e-Poster Now Online at AACR Virtual Meeting 2020
Preclinical Data Confirm the Ability of AsiDNA™ to Reverse Cancer Resistance to PARPi by Preventing Regrowth of Death-Tolerant Cells […]
Tags: AsiDNA™
06/22/2020
Onxeo: report on the Extraordinary General Meeting of June 19, 2020
Paris (France), June 19, 2020 – 5.45 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]
Tags: Financials & Corporate
06/19/2020
Boursoroma – Judith Greciet, Onxeo : «AsiDNA could open a new paradigm in cancer treatment»
Read the interview
Tags: AsiDNA™
06/17/2020
Onxeo offre 10,7% de son capital à Invus – Biotech Finances
(French only) Regards croisés : Interviews of Judith Greciet, CEO of Onxeo, and Mr Nicolas Trebouta, representing Financière de la […]
Tags: Financials & Corporate
06/15/2020
BFM Business Intégrale Bourse : Onxeo, Company of the Day
Interview of Judith Greciet, CEO of Onxeo, following the entry into the capital of Invus, a long-term renowned investor […]
Tags: AsiDNA™, Financials & Corporate
06/10/2020
Onxeo announces a capital increase of €7.3 million by private placement to Invus and Financière de la Montagne, the Company’s historical shareholder
The funds raised will accelerate the development of Onxeo’s programs, and extend its cash runway into Q1 2022 Paris […]
Tags: Financials & Corporate
06/09/2020
Onxeo announces that the Shareholders’ Meeting of May 29, 2020 has approved all ordinary resolutions
The Extraordinary General Meeting will be held on June 19, 2020 on the second call Paris (France), May 29, […]
Tags: Financials & Corporate
05/29/2020
Onxeo Announces Approval of the REVocan Study By Regulatory Authorities
The REVocan study aims to evaluate the abrogation by AsiDNA™ of tumor resistance to a PARP inhibitor in relapsed ovarian […]
Tags: AsiDNA™
Page 1 of 25
Last updated on